Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Active not recruiting 2Unknown 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Uterine Cervical Neoplasms 2Nasopharyngeal Carcinoma 2Stomach Neoplasms 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Locally Advanced Gastric Cancer 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 2Endoscopy 2tremelimumab 1futibatinib 1durvalumab 1Taxes 1Risk Assessment 1Ramucirumab 1Radiofrequency Ablation 1Paclitaxel 1Oxaliplatin 1Observation 1Mass Screening 1Magnetic Resonance Spectroscopy 1Leucovorin 1Itraconazole 1Folfox protocol 1Fluorouracil 1Breath Tests 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Adenocarcinoma Of Esophagus × Taxes × Clear all
NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡